Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Bacil Pharma Ltd has received listing approval from BSE for 84,63,000 equity shares of face value Rs. 10 each, issued at a premium of Rs. 22 per share (total issue price Rs. 32) to non-promoters on a preferential basis. The BSE approval letter is dated June 3, 2025. The aggregate value of this preferential allotment works out to roughly Rs. 27.08 crore. Trading approval is still pending and will be granted only after the company submits NSE approval (if applicable), NSDL/CDSL credit confirmations, and lock-in confirmations for pre-preferential holdings. Shareholders should note this is a dilution event, increasing the total share count of the company.
Existing shareholders will see dilution of their equity stake since these shares are being issued to non-promoters. The issue was done at a premium to face value, which is mildly positive as it signals willingness to pay above par. Wait for actual trading commencement to gauge market reaction.